Toregem’s Anti-USAG-1 Antibody “TRG035” Designated as an Orphan Drug by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Severe Congenital Oligodontia

Toregem BioPharma Co., Ltd. (Head Office: Kyoto City; CEO: Honoka Kiso; hereinafter referred to as Toregem)’s investigational anti-USAG-1 antibody 'TRG035” has been designated by the Ministry of Health, Labour and Welfare as an orphan drug for the target disease “severe congenital hypodontia”.